A detailed history of High Tower Advisors, LLC transactions in Argenx Se stock. As of the latest transaction made, High Tower Advisors, LLC holds 4,671 shares of ARGX stock, worth $2.93 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
4,671
Previous 4,182 11.69%
Holding current value
$2.93 Million
Previous $1.8 Million 40.88%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$434.22 - $551.9 $212,333 - $269,879
489 Added 11.69%
4,671 $2.53 Million
Q2 2024

Aug 13, 2024

BUY
$356.01 - $451.55 $629,069 - $797,888
1,767 Added 73.17%
4,182 $1.8 Million
Q1 2024

May 06, 2024

SELL
$356.95 - $413.29 $434,765 - $503,387
-1,218 Reduced 33.53%
2,415 $950,000
Q4 2023

Feb 12, 2024

SELL
$338.91 - $506.01 $661,213 - $987,225
-1,951 Reduced 34.94%
3,633 $1.38 Million
Q3 2023

Nov 08, 2023

BUY
$369.35 - $548.43 $828,082 - $1.23 Million
2,242 Added 67.09%
5,584 $2.75 Million
Q2 2023

Aug 14, 2023

BUY
$360.14 - $422.58 $667,339 - $783,040
1,853 Added 124.45%
3,342 $1.3 Million
Q1 2023

May 11, 2023

SELL
$334.23 - $403.65 $26,069 - $31,484
-78 Reduced 4.98%
1,489 $554,000
Q4 2022

Feb 08, 2023

SELL
$342.17 - $402.31 $192,983 - $226,902
-564 Reduced 26.47%
1,567 $593,000
Q3 2022

Nov 09, 2022

BUY
$343.2 - $395.75 $24,024 - $27,702
70 Added 3.4%
2,131 $752,000
Q2 2022

Aug 10, 2022

BUY
$269.58 - $378.88 $9,974 - $14,018
37 Added 1.83%
2,061 $781,000
Q1 2022

May 12, 2022

BUY
$254.45 - $351.06 $366,916 - $506,228
1,442 Added 247.77%
2,024 $636,000
Q4 2021

Feb 10, 2022

BUY
$272.01 - $353.03 $158,309 - $205,463
582 New
582 $203,000

Others Institutions Holding ARGX

About ARGENX SE


  • Ticker ARGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,323,800
  • Market Cap $34.8B
  • Description
  • argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...
More about ARGX
Track This Portfolio

Track High Tower Advisors, LLC Portfolio

Follow High Tower Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of High Tower Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on High Tower Advisors, LLC with notifications on news.